1,24,25-三羟基维生素d2 | 100496-04-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: 1,24,25-三羟基维生素d2
• 英文名称: 1,24,25-Trihydroxyergocalciferol
• 英文别名: (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dihydroxy-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
• CAS: 100496-04-6
• 化学式: C₂₈H₄₄O₄
• 分子量: 444.6
• InChiKey: KRGCLKZOZQUAFK-ABEKVIRTSA-N

物化性质

• 物理描述：
  Solid

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  32
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  80.9
• 氢给体数：
  4
• 氢受体数：
  4

文献信息

• Methods for preparation and use of 1alpha,24(S)-dihydroxyvitamin D2
  申请人：Bone Care International, Inc.

  公开号：US20040009958A1

  公开（公告）日：2004-01-15

  A method of inhibiting the hyperproliferation of malignant or neoplastic cells, comprising treating the cells with an antiproliferative amount of 1&agr;,24(S)-dihydroxyvitamin D 2 . The method also includes the co-administration of cyotoxic agents with the 1&agr;,24(S)-dihydroxyvitamin D 2 .

  一种抑制恶性或肿瘤细胞过度增殖的方法，包括使用抗增殖量的1&agr;，24(S)-二氢维生素D2处理细胞。该方法还包括与1&agr;，24(S)-二氢维生素D2共同给药细胞毒剂。
• Methods for preparation of 1 alpha, 24-dihydroxy vitamin D2
  申请人：BONE CARE INTERNATIONAL, INC.

  公开号：EP0914825A2

  公开（公告）日：1999-05-12

  1α,24-dihydroxy vitamin D2 which is useful as an active compound of pharmaceutical compositions for the treatment of disorders of calcium metabolism and for various skin disorders. The invention also includes preparation of synthetic 1α,24-dihydroxy vitamin D2 starting from ergosterol which is converted in six steps to 24-hydroxyergosterol. 24-hydroxyergosterol is irradiated and thermally converted to 24-hydroxy vitamin D2 which is converted in five steps to 1α,24-dihydroxy vitamin D2. The syntheses also produce novel intermediates.

  1α,24-二羟基维生素 D2 可作为药物组合物的活性化合物，用于治疗钙代谢紊乱和各种皮肤病。本发明还包括制备合成的 1α,24-二羟基维生素 D2，它以麦角甾醇为原料，经过六个步骤转化为 24-羟基麦角甾醇。24- 羟基麦角甾醇经过辐照和热转化为 24- 羟基维生素 D2，再经过五个步骤转化为 1α,24-二羟基维生素 D2。合成过程中还会产生新的中间产物。
• Treatment of hyperproliferative diseases using active vitamin D analogues
  申请人：Bone Care International, Inc.

  公开号：US20020128240A1

  公开（公告）日：2002-09-12

  The present invention provides a method of inhibiting the hyperproliferative cellular activity of neoplasms and other hyperproliferative diseases with an active vitamin D compound utilizing a high dose, episodic treatment protocol.

  本发明提供了一种利用大剂量、偶发性治疗方案，用活性维生素 D 复合物抑制肿瘤和其他增殖亢进疾病的增殖亢进细胞活性的方法。
• Method for treating and preventing hyperparathyroidism
  申请人：Bone Care International, Inc.

  公开号：US20020183288A1

  公开（公告）日：2002-12-05

  This invention relates to a method for treating or preventing hyperthyroidism associated with aging and/or with Aging-Related Vitamin D Deficiency (ARVDD) syndrome by administering a sufficient amount of an active vitamin D compound utilizing a variety of effective treatment protocols. The invention further relates to treating or preventing one or more of the following conditions, e.g., (1) primary vitamin D deficiency, (2) 1,25-(OH) 2 D 3 deficiency, and (3) 1,25-(OH) 2 D 3 resistance included within the syndrome of ARVDD.

  本发明涉及一种治疗或预防与衰老和/或与衰老相关的维生素D缺乏（ARVDD）综合征有关的甲状腺机能亢进症的方法，其方法是利用各种有效的治疗方案施用足量的活性维生素D化合物。本发明进一步涉及治疗或预防以下一种或多种病症，例如：（1）原发性维生素 D 缺乏症；（2）1,25-（OH） 2 D 3 缺乏症，以及 (3) 1,25-(OH) 2 D 3 抗性被纳入 ARVDD 综合征。
• 1-HYDROXYLATION PROCESS
  申请人：WISCONSIN ALUMNI RESEARCH FOUNDATION

  公开号：EP0077353A1

  公开（公告）日：1983-04-27